TROPOS
Are You Eligible?The purpose of this study is to determine the safety and effectiveness of a new Pulmonary Artery Hypertension therapy for patients who are already receiving treatment for PAH.
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
Pulmonary Hypertension is a serious condition characterised by high blood pressure in the blood vessels of the lungs. Unlike regular blood pressure measured in the arm, PH refers to the pressure inside the vessels within the lungs, which can only be confirmed through an invasive procedure. This elevated lung pressure causes patients to feel short of breath and, if left untreated, can ultimately lead to right heart failure and death.
Historically, PH had a very poor prognosis, with patients living just over two years on average. However, the development of new therapies has allowed some patients to now live 10 to 15 years with the condition.
The purpose of this study is to determine the safety and effectiveness of a new PAH therapy for patients who are already receiving treatment for PAH.
To learn more about the Phase II study visit https://clinicaltrials.gov/study/NCT05975905
TROPOS
Eligibility
- Patients with Pulmonary artery hypertension who are on stable therapy
- Over 18 years
- BMI <35
Lead investigator
- Dr John Feenstra
Clinical trial coordinator
- Bronwen Field
Technical title
A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of KER-012 in Combination with Background Therapy in Adult Participants with Pulmonary Arterial Hypertension
Contact Us
If you would like more information about this clinical trial, please complete the contact form below.